Onconic Therapeutics Inc. (KOSDAQ:476060)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Biotechnology	21.06B	95.00M	60.00M
Biotechnology Growth	22064.25%	58.33%	-
Total	21.06B	95.00M	60.00M
Total Growth	22064.25%	58.33%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
South Korea	21.06B	95.00M	60.00M
South Korea Growth	22064.25%	58.33%	-
Total	21.06B	95.00M	60.00M
Total Growth	22064.25%	58.33%	-

Source: S&P Global Market Intelligence.